Plus de 40 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Optimizing a deployable high efficacy malaria vaccine (OptiMalVax)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in ...
Voir le projet
17
Participants partenaires
TERMINÉ
An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2021,
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet
43
Participants partenaires
TERMINÉ
Recirculated tissue macrophages (TiMa) in blood: Novel approach to early diagnosis and treatment monitoring in oncology (TiMaScan)
Date du début: 1 nov. 2016, Date de fin: 31 oct. 2021,
In the ageing European population, cancer has become the most common cause of death. Consequently, screening programs aim at early detection of cancer, while scanning/imaging technologies, serum assays and regular biopsies aim at monitoring of treatment effectiveness to improve cure rates and increase quality-of-life, thereby also attempting to reduce health care costs. However, in many cases the ...
Voir le projet
1
Participant partenaire
TERMINÉ
The ER located master regulation of endosomal positioning and further movements (ERCOPE)
Date du début: 1 sept. 2016, Date de fin: 31 août 2021,
The endo-lysosomal system is critical to diverse processes, including protein homeostasis, signaling and antigen presentation. The vesicular compartment is organized as a collective unit wherein the bulk of endosomes derived from disparate origins resides in a cloud in the perinuclear region and extends outwards to include quickly moving vesicles in the periphery. At this busy intersection between ...
Voir le projet
1
Participant partenaire
TERMINÉ
Characterisation Of A Green Microenvironment And To Study Its Impact Upon Health and Well-Being in The Elderly As A Way Forward For Health Tourism. (CHARMED)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
Our society in Europe is still under prepared for the demographic changing situation of an ageing population which began several decades ago. This is visible in the age structure of the population and is reflected by the fact that the population aged 65 years and over is increasing in every European country. The growth in the elderly population may be explained by increased longevity, but at the s ...
Voir le projet
19
Participants partenaires
TERMINÉ
New therapies for uveal melanoma (UM Cure 2020)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or ...
Voir le projet
13
Participants partenaires
TERMINÉ
Boost Brittle Bones Before Birth (BOOSTB4)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal m ...
Voir le projet
13
Participants partenaires
TERMINÉ
Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and ...
Voir le projet
16
Participants partenaires
TERMINÉ
European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN_ACTI2NG)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors an ...
Voir le projet
11
Participants partenaires
TERMINÉ
Resetting the THYRoid axis for prevention of AGE-related diseases and co-morbidities (THYRAGE)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
We hypothesize that inappropriate thyroid hormone action in target cells is a common mechanism underlying susceptibility to age-related degenerative diseases and co-morbidities. Although regulation of systemic thyroid status is well understood and underpins treatment of common thyroid disease, it is only in the last decade that the importance of local regulation of thyroid hormone action in tissue ...
Voir le projet
7
Participants partenaires
TERMINÉ
Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)
Date du début: 1 juin 2015, Date de fin: 30 nov. 2020,
The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Voir le projet
25
Participants partenaires
TERMINÉ
Novel materials to improve magnetic resonance imaging (NOMA-MRI)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,
MRI is one of the most important human clinical imaging modalities. Over the past decade many technological advances have improved image quality substantially. One of the critical trends has been the move towards higher magnetic fields, which has transformed many clinical applications, but has also introduced significant challenges. These higher fields correspond to higher operating frequencies, ...
Voir le projet
1
Participant partenaire
TERMINÉ
Stem Cells for Cardiac Arrhythmia Risk Assessment (STEMCARDIORISK)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,
Among the most significant conceptual changes in stem cell biology of the past decade has been the use of human pluripotent stem cells (hPSCs) for disease modelling and drug development rather than solely as therapeutics. One area of major interest in this context is that of arrhythmic disorders of the heart. Cardiac arrhythmias are a leading cause of death among young people, with inherited forms ...
Voir le projet
1
Participant partenaire
TERMINÉ
Exploitation of Glycosylation Signatures for Precision Medicine (GlySign)
Date du début: 1 oct. 2016, Date de fin: 30 sept. 2020,
GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive changes occur in the glycomics profiles or - Glycan Signatures - of human glycoproteins during progression of many chronic diseases including cancer and inflammatory conditions. The three beneficiaries of the GlySign Consortium have been instrumental in contr ...
Voir le projet
3
Participants partenaires
TERMINÉ
Beta Cell Generation by Stem Cell-Derived Implants in Diabetes (BetaCellTherapy)
Date du début: 1 déc. 2015, Date de fin: 31 août 2020,
Despite improved treatment, diabetes remains a chronic disease with major health risks and heavy burden on patients and society. Serious forms are caused by depletion in pancreatic beta cells and associated loss in insulin’s homeostatic control throughout life. Their cure requires restoration of a metabolically adequate beta cell mass. Implants of beta cell grafts prepared from human pancreases ha ...
Voir le projet
8
Participants partenaires
TERMINÉ
A Clinical Decision Support system based on Quantitative multimodal brain MRI for personalized treatment in neurological and psychiatric disorders (CDS-QUAMRI)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
A large number of neurological and psychiatric disorders lack objective criteria for primary diagnoses, early differential diagnosis with regard to subtypes in treatment response and disease progression or effective therapy monitoring resulting in a tremendous negative socio-economic impact. Scientific studies based on advanced MRI methods indicate that related patients show specific subtle change ...
Voir le projet
7
Participants partenaires
TERMINÉ
Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) (BRIDGES)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up th ...
Voir le projet
20
Participants partenaires
TERMINÉ
Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,
Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet
44
Participants partenaires
TERMINÉ
Zoonotic Anticipation and Preparedness Initiative (ZAPI)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on public and/or veterinary health as well as disruptive effects on sector, regional or even global economy. The predominantly zoonotic nature of emerging pathogens calls for a One Health approach uniting the human medical and veterinary fields, dedicated to swiftly ...
Voir le projet
21
Participants partenaires
TERMINÉ
IN SITU IMAGING OF LIVING TISSUES WITH CELLULAR SPATIAL RESOLUTION (HISTO-MRI)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,
The main objective of HISTO-MRI project is to develop the technologies that will enable the non-invasive visualization of individual human cells in vivo and in real time, based on a radical new Magnetic Resonance Imaging concept: High Frequency Pulsed MRI. To accomplish this ambitious objective, several new challenging multidisciplinary technologies will have to be developed: 1) new method for the ...
Voir le projet
7
Participants partenaires
TERMINÉ
Image-Guided Surgery (IGS) and Personalised Postoperative Immunotherapy To Improving Cancer Outcome (ISPIC)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
The basic concept of our proposal is to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of c ...
Voir le projet
14
Participants partenaires
TERMINÉ
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) (SCIDNET)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for ...
Voir le projet
13
Participants partenaires
TERMINÉ
Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medic ...
Voir le projet
14
Participants partenaires
TERMINÉ
Restoring tissue regeneration in patients with visceral Graft versus Host Disease. (RETHRIM)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or organ injury. Regeneration relies on tissue or organ-specific stem and progenitor cells, but can also aim at promoting the endogenous repair capacity of the body. Mesenchymal stromal cells (MSC) are undergoing clinical testing in a variety of clinical conditions ...
Voir le projet
12
Participants partenaires
TERMINÉ
Tools and TECHNOlogies for Breakthrough in hEArt Therapies (TECHNOBEAT)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Cardiovascular diseases including myocardial infarction (MI), which entails the irreversible loss of heart muscle tissue, constitute a major socio-economic burden in global healthcare. With whole organ transplantation as the only treatment option for end-stage heart failure, MI patients could particularly benefit from advanced cell therapies aimed at the functional reconstitution of damaged hearts ...
Voir le projet
8
Participants partenaires
TERMINÉ
Infrastructure for NMR, EM and X-rays for translational research (iNEXT)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
Structural biology provides insight into the molecular architecture of cells up to atomic resolution, revealing the biological mechanisms that are fundamental to life. It is thus key to many innovations in chemistry, biotechnology and medicine such as engineered enzymes, new potent drugs, innovative vaccines and novel biomaterials.iNEXT (infrastructure for NMR, EM and X-rays for Translational rese ...
Voir le projet
23
Participants partenaires
TERMINÉ
Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therapeutics (GlyCoCan)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
Colorectal cancer (CRC) is a major worldwide cancer burden with about 1.4 million cases in 2012 and an annual mortality of approximately 700,000. Early detection is crucial as treatment is most efficient in early stages where population based screenings could substantially reduce incidence and mortality.Current screening techniques are invasive or lack sensitivity and specificity. Moreover, the mo ...
Voir le projet
9
Participants partenaires
TERMINÉ
Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study (MOGLYNET)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for:- creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills- exploiting this platform to train a new generati ...
Voir le projet
5
Participants partenaires
TERMINÉ
POWER2DM - Predictive model-based decision support for diabetes patient empowerment (POWER2DM)
Date du début: 1 févr. 2016, Date de fin: 31 juil. 2019,
The main objective of POWER2DM is to develop and validate a personalized self-management support system (SMSS) for T1 and T2 diabetes patients that combines and integrates (1) a decision support system (DSS) based on leading European predictive personalized models for diabetes interlinked with predictive computer models, (2) automated e-coaching functionalities based on Behavioural Change Theories ...
Voir le projet
8
Participants partenaires
TERMINÉ
Simulation Modeling of coronary ARTery disease: a tool for clinical decision support (SMARTool)
Date du début: 1 janv. 2016, Date de fin: 30 juin 2019,
SMARTool aims at developing a platform based on cloud technology, for the management of patients with coronary artery disease (CAD) by standardizing and integrating heterogeneous health data, including those from key enabling technologies. The platform includes existing multiscale and multilevel ARTreat (FP7-224297) models of coronary plaque progression based on non-invasive coronary CT angiograph ...
Voir le projet
11
Participants partenaires
TERMINÉ
MELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival (MELGEN)
Date du début: 1 juin 2015, Date de fin: 31 mai 2019,
MELGEN (MELanoma GENetics) – understanding and biomarking the genetic and immunological determinants of melanoma survivalThe MELGEN European Training Network (ETN) will create an environment for long-term, collaborative, inter-sectorial cancer genetics research with the ultimate aim of improving precision (personalised) medicine. In a 2012 report the European Science Foundation identified the impo ...
Voir le projet
7
Participants partenaires
TERMINÉ
Advancing Smart Optical Imaging and Sensing for Health (ASTONISH)
Date du début: 1 juin 2016, Date de fin: 31 mai 2019,
The ageing population and related increase in chronic diseases put considerable pressure on both the healthcare system and the society, resulting in an unsustainable rise of healthcare costs. As a result there is an urgent need to improve efficiency of care and reduce hospitalisation time in order to control cost and increase quality of life. Addressing this need, medical applications need to beco ...
Voir le projet
25
Participants partenaires
TERMINÉ
Aggression in Children: Unraveling gene-environment interplay to inform Treatment and InterventiON strateg (ACTION)
Date du début: 1 juin 2014, Date de fin: 31 mai 2019,
Aggression inflicts a huge personal, psychological and financial burden on affected individuals, their relatives, and society at large. Despite large scientific, preventive, and treatment investments, no decrease in aggressive behavior is seen. This calls for a shift to new approaches. By capitalising on comprehensive longitudinal cohorts, recent advances in genetic, biological, epidemiological, a ...
Voir le projet
12
Participants partenaires
TERMINÉ
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation repr ...
Voir le projet
12
Participants partenaires
TERMINÉ
European Virus Archive goes global (EVAg)
Date du début: 1 avr. 2015, Date de fin: 31 mars 2019,
The overall objective will be to create and mobilise an International network of high calibre centres around a strong European group of institutes selected for their appropriate expertises, to collect, amplify, characterise, standardise, authenticate, distribute and track, mammalian and other exotic viruses. The network of EVAg laboratories including 25 institutions represents an extensive range o ...
Voir le projet
27
Participants partenaires
TERMINÉ
Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2019,
ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro ...
Voir le projet
7
Participants partenaires
TERMINÉ
Aortic Valve Replacement using Individualised Regenerative Allografts: Bridging the Therapeutic Gap (ARISE)
Date du début: 1 janv. 2015, Date de fin: 31 mars 2019,
65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. In affected patients, mortality without AVR is extremely high and 50 % die within 2 years. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. ...
Voir le projet
9
Participants partenaires
TERMINÉ
European Training Network on Antiviral Drug Development (ANTIVIRALS)
Date du début: 1 mars 2015, Date de fin: 28 févr. 2019,
Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other impor ...
Voir le projet
12
Participants partenaires
TERMINÉ
CHROMATIN-REPAIR-CODE: Hacking the chromatin code for DNA repair (CHROMATINREPAIRCODE)
Date du début: 1 mars 2014, Date de fin: 28 févr. 2019,
"Our cells receive tens of thousands of different DNA lesions per day. Failure to repair these lesions will lead to cell death, mutations and genome instability, which contribute to human diseases such as neurodegenerative disorders and cancer. Efficient recognition and repair of DNA damage, however, is complicated by the fact that genomic DNA is packaged, through histone and non-histone proteins, ...
Voir le projet
1
Participant partenaire
TERMINÉ
Preclinical Intra-Operative Image-Guided Surgery and Post-Operative Radiotherapy of Tumours (PRISAR)
Date du début: 1 févr. 2015, Date de fin: 31 janv. 2019,
The main objective and basic concept of our proposal is to improve intra-operative and post-operative targeted surgical probes and new detection systems for surgical intervention of cancer. The work revolves around the mobility of clinicians, scientists and technologists between twelve consortium partners and across four different countries. The goal is the implementation of inter-disciplinary, in ...
Voir le projet